ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 61685.1 IP-LS
• Titre du projet anglais: ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

Description succincte (Allemand)

ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

Description succincte (Anglais)

ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies

Résumé des résultats (Abstract) (Allemand)

We will deliver ONCONIX: a highly innovative personalized treatment-response prediction platform for oncology based on uniquely rapid patient-derived organoid cultures and in-house developed machine learning models. Here, we will perform a non-interventional proof-of-concept study in bladder cancer.